Chest
Volume 151, Issue 6, June 2017, Pages 1201-1203
EditorialThe Answer for Inhaled Antibiotics in Pneumonia Is Still Blowing in the Wind
References (11)
- et al.
A randomized trial of the amikacin fosfomycin inhalation system for the adjunctive therapy of Gram-negative ventilator-associated pneumonia: IASIS trial
Chest
(2017) - et al.
International study of the prevalence and outcomes of infection in intensive care units
JAMA
(2009) - et al.
Infections, antibiotic treatment and mortality in patients admitted to ICUs in countries considered to have high levels of antibiotic resistance compared to those with low levels
BMC Infect Dis
(2014) - et al.
Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study
Crit Care
(2014) - et al.
Using the number needed to treat to assess appropriate antimicrobial therapy as a determinant of outcome in severe sepsis and septic shock
Crit Care Med
(2014)
There are more references available in the full text version of this article.
Cited by (3)
Efficient degradation of ciprofloxacin by a flower-spherical Bi<inf>2</inf>MoO<inf>6</inf>/BiOCl Z-type heterojunction photocatalyst enriched with oxygen vacancies
2023, Journal of Environmental Chemical EngineeringThe Unfulfilled Promise of Inhaled Therapy in Ventilator-Associated Infections: Where Do We Go from Here?
2022, Journal of Aerosol Medicine and Pulmonary Drug DeliveryHow should aerosols be delivered during invasive mechanical ventilation?
2017, Respiratory Care
FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to CHEST the following: A. F. S. has served as a speaker for, consultant to, or received research support from Achaogen, Actavis, Astellas, Astra Zeneca, Bayer, BMS, Cardeas, Cempra, Medicines Company, Melinta, Merck, Paratek, Pfizer, Roche, Shionogi, Spero, Tetraphase, and Theravance. M. D. Z. has received consulting fees and/or research funding from Achaogen, Astellas, The Medicines Company, Melinta, Merck, Pfizer, Shionogi, Tetraphase, and Theravance.
© 2016 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.